Mineralys Therapeutics

MLYS

Market cap $2.73B

Overview Fund Activity

35.20 USD

-1.90

5.12%

At close Updated Sep 15, 2:07 PM EDT

1 day

-5.12%

5 days

-4.03%

1 month

142.42%

3 months

161.71%

6 months

147.54%

Year to date

187.35%

1 year

203.45%

5 years

90.89%

10 years

90.89%

About: Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Employees: 51

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

153% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 30

67% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 24

10% more funds holding

Funds holding: 149 [Q1] → 164 (+15) [Q2]

3.37% more ownership

Funds ownership: 97.42% [Q1] → 100.78% (+3.37%) [Q2]

9% less capital invested

Capital invested by funds: $971M [Q1] → $889M (-$82.6M) [Q2]

10% less funds holding in top 10

Funds holding in top 10: 10 [Q1] → 9 (-1) [Q2]

97% less call options, than puts

Call options by funds: $30K | Put options by funds: $1.11M

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$26

26% downside

Avg. target

$43

21% upside

High target

$52

48% upside

5 analyst ratings

4 positive

80%

1 neutral

20%

0 negative

0%

Wells Fargo Mohit Bansal	$50	Overweight Maintained	11 Sep 2025
Goldman Sachs Richard Law	$52	Buy Maintained	9 Sep 2025
HC Wainwright & Co. Matthew Caufield	$42	Buy Reiterated	8 Sep 2025
Jefferies Dennis Ding	$26	Hold Maintained	3 Sep 2025
B of A Securities Greg Harrison	$43	Buy Maintained	28 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about MLYS published over the past 30 days

Zacks Investment Research

What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now?

Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now?

The Motley Fool

These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts

Investors in search of stocks that can produce dramatic gains in a short time frame will want to turn their heads toward the healthcare sector. A handful of stocks in the space more than doubled in price recently.

These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the closing of its previously announced underwritten public offering of 11,274,509 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase up to 1,470,588 additional shares of its common stock, at a public offering price of $25.50 per share. The aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $287.5 million. All of the securities sold in the offering were sold by Mineralys.

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 150 points on Wednesday.

Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the pricing of an upsized underwritten public offering of 9,803,921 shares of its common stock at a public offering price of $25.50 per share. The aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $250.0 million. In addition, Mineralys has granted the underwriters a 30-day option to purchase up to an additional 1,470,588 shares of its common stock. All of the securities to be sold in the offering are to be sold by Mineralys. The offering is expected to close on or about September 4, 2025, subject to the satisfaction of customary closing conditions.

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that it has commenced an underwritten public offering of $175.0 million of shares of its common stock.

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Zacks Investment Research

Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 149.7% in Mineralys Therapeutics, Inc. (MLYS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade

Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call Transcript

Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Adam Scott Levy - CFO & Secretary Eric Warren - Chief Commercial Officer Jon Congleton - President, CEO & Director Daniel Ferry - Managing Director, Lifesci Advisors, LLC Conference Call Participants Alice Jennifer Nettleton - BofA Securities, Research Division Jayed Momin - Stifel, Nicolaus & Company, Incorporated, Research Division Matthew Coleman Caufield - H.C. Wainwright & Co, LLC, Research Division Michael DiFiore - Unidentified Company Evercore - Unidentified Company Rami Azeez Katkhuda - LifeSci Capital, LLC, Research Division Richard J.

Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call Transcript

Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

– Presented and published the positive results from both the Launch-HTN and Advance-HTN pivotal trials at scientific meetings and in JAMA and NEJM – – Pre-NDA meeting scheduled to take place in 4Q 2025 – – Explore-CKD Phase 2 trial successfully achieved statistical significance in reduction of systolic BP and UACR, and demonstrated a favorable safety profile – – Explore-OSA Phase 2 trial in OSA participants with hypertension is ongoing; topline results anticipated in 1H 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa.

Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

See News Rankings

Charts implemented using Lightweight Charts™